BIOMARKERS AND DRIVING PERFORMANCE IN PRECLINICAL ALZHEIMER DISEASE AMONG AFRICAN AMERICANS AND CAUCASIANS

非裔美国人和白人临床前阿尔茨海默病的生物标志物和驱动表现

• 批准号: 9455431
• 负责人: Ganesh M Babulal
• 金额: $ 7.63万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9455431
• 关键词: Address; African American; Age; Age-Years; Aging; Alzheimer' s Disease; Alzheimer' s disease risk; Apolipoprotein E; Articular Range of Motion; Automobile Driving; Behavior; Behavioral; Biological; Biological Markers; Biostatistical Methods; Blood Vessels; Caring; Caucasians; Cerebrospinal Fluid; Cessation of life; Cognition; Cognitive; Complex; Conduct Clinical Trials; Data; Dementia; Development; Diagnosis; Diagnostic; Disease; Education; Elderly; Evaluation; Future; Gerontology; Goals; High Prevalence; Hippocampus (Brain); Injury; Intervention; Intervention Trial; Knowledge; Link; Location; Magnetic Resonance Imaging; Measurement; Measures; Medical; Memory; Methods; Minority; Motor; Parents; Participant; Pattern Recognition; Performance; Pharmacology; Pilot Projects; Population; Poverty; Prevalence; Psychometrics; Public Health; Quality of life; Race; Research; Risk; Risk Factors; Safety; Scientist; Speed; Stress; Symptoms; TREM2 gene; Testing; Time; Training; Transportation; United States; Vehicle crash; Work; aged; aging brain; amyloid imaging; cognitive testing; cohort; disease diagnosis; driving behavior; executive function; experience; eye hand coordination; functional outcomes; gray matter; health disparity; high risk; improved; multidisciplinary; neuroimaging marker; novel; pre-clinical; racial difference; skills; tau Proteins; vascular factor

PROJECT SUMMARY/ABSTRACT The goal of this pilot study is to examine whether aged African Americans and Caucasians differ in driving behaviors, and if so, whether these differences are linked to Alzheimer’s Disease (AD) biomarkers, as well as vascular risk factors. Our research indicates that driving decline among older adults, an important functional outcome, is predicted by preclinical AD. However, little is known about driving behavior specifically in African American older adults. Closing this knowledge gap soon is critical, since African Americans are at twice the risk of symptomatic AD compared to Caucasians. This research is significant because 36 million licensed drivers are aged 65 years or older, and the number of older adults in the United States is expected to double by 2050, when 1 in 4 drivers will be 65 years or older. Motor vehicle crashes are a leading cause of injury and death in older adults. Research on older African American drivers, to date, has only looked at driving cessation, and has not examined AD and cognition. The ability to identify who will be at most risk of driving decline and to predict when decline will occur would inform early driving safety intervention trials for older adults. Our Specific Aims will test whether AD biomarker values interact with race and vascular risk factors (VRF) in predicting driving behavior over a one-year period: (1) We will determine, among cognitively normal older adults (N=60) whether there are racial differences in driving performance and behavior while adjusting for VRF, over a one-year period. (2) We will test whether factors known to be associated with AD predict driving performance and behavior by examining the three-factor interaction between race, AD biomarkers and VRF. To test these Specific Aims, we have assembled a multidisciplinary team with expertise in AD, neuroimaging biomarkers, CSF biomarkers, driving generally, naturalistic driving specifically, cognitive and brain aging, gerontology and longitudinal biostatistical methods. We will capitalize on our parent R01 by following a subset (N=30 African American, 30 Caucasian) of cognitively normal participants with and without preclinical AD. Each participant will take part in an annual, on-road driving evaluation to measure driving performance, as well as have their driving behavior captured daily, using a naturalistic method that collects data on date, time, speed, longitude and latitude each time a participant drives their vehicle. We will test whether AD biomarker values and vascular risk factors interact with race in predicting driving performance and behavior. If the interaction between AD biomarkers and race is significant, this would stress the importance of obtaining biomarker measurements in research. These data may be valuable when seeking to explain the higher rate of AD development among African Americans, and in conducting clinical trials.

项目总结/摘要 这项初步研究的目的是检查老年非裔美国人和高加索人在以下方面是否存在差异： 驾驶行为，如果是这样，这些差异是否与阿尔茨海默病（AD）生物标志物有关， 以及血管风险因素。我们的研究表明，老年人驾驶能力的下降， 功能结果，由临床前AD预测。然而，很少有人知道驾驶行为，特别是在 非裔美国老年人。尽快缩小这一知识差距至关重要，因为非洲裔美国人的年龄是美国人的两倍。 与白人相比，症状性AD的风险。 这项研究意义重大，因为3600万持牌司机年龄在65岁或以上， 到2050年，美国老年人的数量预计将翻一番，届时每4名驾驶员中就有1名65岁 或者更老机动车碰撞是老年人受伤和死亡的主要原因。老年人研究 到目前为止，非洲裔美国司机只看了停止驾驶，还没有检查AD和 认知.能够识别谁将面临驾驶能力下降的最大风险，并预测何时会出现下降 将为老年人的早期驾驶安全干预试验提供信息。 我们的特定目标将测试AD生物标志物值是否与种族和血管风险因素相互作用 (VRF)在预测驾驶行为超过一年的时间：（1）我们将确定，在认知正常 老年人（N=60）在调整驾驶性能和行为时是否存在种族差异 自愿成果基金，为期一年。(2)我们将测试已知与AD相关的因素是否能预测驾驶 通过检查种族、AD生物标志物和VRF之间的三因素相互作用来评估表现和行为。 为了测试这些特定目标，我们组建了一个具有AD专业知识的多学科团队， 神经成像生物标志物，CSF生物标志物，一般驾驶，具体自然驾驶，认知和 脑老化、老年学和纵向生物统计学方法。我们将利用我们的母公司R 01， 在一个认知正常的参与者子集（N=30名非洲裔美国人，30名高加索人）中， 临床前AD。每个参与者将参加年度道路驾驶评估，以衡量驾驶 性能，以及每天捕捉他们的驾驶行为，使用自然主义的方法， 数据的日期，时间，速度，经度和纬度的参与者每次驾驶他们的车辆。 我们将测试AD生物标志物值和血管危险因素是否与种族在预测AD发病率方面相互作用。 驾驶性能和行为。如果AD生物标志物和种族之间的相互作用是显著的， 强调在研究中获得生物标志物测量的重要性。这些数据可能是有价值的， 寻求解释非裔美国人中AD发病率较高的原因，并在进行临床研究时， 审判